TransMedics Stock Trading Halted Today; FDA Advisory Committ

TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Heart System


TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Heart System
News provided by
Share this article
Share this article
ANDOVER, Mass., April 6, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that Nasdaq has halted trading of the company's common stock.
The U.S. Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee is meeting today to review TransMedics' Organ Care System™ (OCS) Heart System. The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve a donated heart in a near-physiologic, beating and perfused state, while continually monitoring and optimizing heart function for eventual transplantation into the recipient.

Related Keywords

Andover , Massachusetts , United States , , Transmedics Inc , Transmedics Group Inc , Drug Administration , Advisory Committee , Nasdaq , Transmedics Group , Circulatory System Devices Panel , Medical Devices Advisory Committee , Transmedic Organ Care System , Heart System , Annual Report , Transmedics , Inc , ஆண்டோவர் , மாசசூசெட்ஸ் , ஒன்றுபட்டது மாநிலங்களில் , நாஸ்டாக் , சுற்றோட்ட அமைப்பு சாதனங்கள் குழு , இதயம் அமைப்பு , ஆண்டு அறிக்கை , இன்க் ,

© 2025 Vimarsana